Paper856255
Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid.
Wei CM and 1 other. Biochemistry, 1977. Cited by 234 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid. Papers, record 856255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/856255
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenosine | Major topic |
| HeLa Cells | Major topic |
| RNA, Messenger | Major topic |
| Base Sequence | |
| Oligoribonucleotides | |
| Poly A | |
| Ribonucleotides |
Source PubMed
Cited by157
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 234 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42239405 | FTO separation-of-function mutations alter m6A versus m6Am demethylation selectivity on RNA. | bioRxiv | 2026 | https://conductscience.org/library/papers/42239405 | PubMed |
| 42136125 | RBM45 Preferential Binding to m6A: Simulations Suggest Synergy of RRM3 and Other Domains. | J Phys Chem B | 2026 | https://conductscience.org/library/papers/42136125 | PubMed |
| 41935327 | Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/41935327 | PubMed |
| 41738031 | Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. | J Natl Cancer Cent | 2026 | https://conductscience.org/library/papers/41738031 | PubMed |
| 41662154 | Mechanistic studies on HNRNPA2B1 suggest binding but not selective recognition of m6A. | RNA Biol | 2026 | https://conductscience.org/library/papers/41662154 | PubMed |
| 41598234 | Discovering, Integrating, and Reinterpreting the Molecular Logic of Life: From Classical Theories of Heredity to an Extended Functional Perspective on the Central Dogma. | Life (Basel) | 2026 | https://conductscience.org/library/papers/41598234 | PubMed |
| 41188020 | Aberrant NSUN1 activity connects m5C-RNA modification to TDP-43 neurotoxicity in ALS/FTD. | Life Sci Alliance | 2026 | https://conductscience.org/library/papers/41188020 | PubMed |
| 41137957 | FTO promotes the progression of triple-negative breast cancer by regulating the m6A methylation of NFKBIE. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41137957 | PubMed |
| 41019992 | Role of N6-Methyladenosine (m6A) epitranscriptomic mark in regulating viral infections and target for antiviral development. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41019992 | PubMed |
| 40940799 | m6A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading. | Cells | 2025 | https://conductscience.org/library/papers/40940799 | PubMed |
| 40724951 | From Detection to Prediction: Advances in m6A Methylation Analysis Through Machine Learning and Deep Learning with Implications in Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40724951 | PubMed |
| 40642107 | Potential role of N6-methyladenosine modification in circular RNA biogenesis and function in the inflammatory responses. | Front Mol Med | 2025 | https://conductscience.org/library/papers/40642107 | PubMed |
| 40247118 | Small-molecule-catalysed deamination enables transcriptome-wide profiling of N6-methyladenosine in RNA. | Nat Chem | 2025 | https://conductscience.org/library/papers/40247118 | PubMed |
| 40022434 | The m6A demethylase FTO promotes C/EBPβ-LIP translation to perform oncogenic functions in breast cancer cells. | FEBS J | 2025 | https://conductscience.org/library/papers/40022434 | PubMed |
| 39959203 | Regulatory mechanisms of m6A methylation in dilated cardiomyopathy. | Am J Transl Res | 2025 | https://conductscience.org/library/papers/39959203 | PubMed |
| 39831771 | The interplay between RNA m6A modification and radiation biology of cancerous and non-cancerous tissues: a narrative review. | Cancer Biol Med | 2025 | https://conductscience.org/library/papers/39831771 | PubMed |
| 39705353 | Cancer mutations rewire the RNA methylation specificity of METTL3-METTL14. | Sci Adv | 2024 | https://conductscience.org/library/papers/39705353 | PubMed |
| 39532922 | METTL3 alters capping enzyme expression and its activity on ribosomal proteins. | Sci Rep | 2024 | https://conductscience.org/library/papers/39532922 | PubMed |
| 39037148 | A primer for junior trainees: Recognition of RNA modifications by RNA-binding proteins. | Biochem Mol Biol Educ | 2024 | https://conductscience.org/library/papers/39037148 | PubMed |
| 38764000 | Genetic regulation of m6A RNA methylation and its contribution in human complex diseases. | Sci China Life Sci | 2024 | https://conductscience.org/library/papers/38764000 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/856255
GET https://conductscience.org/api/papers/v1/856255/cited_by?page=2